A randomized controlled study of the efficacy of Tadalafil monotherapy versus combination of Tadalafil and mirabegron for the treatment of overactive bladder (OAB) associated with benign prostatic hyperplasia (BPH)
Latest Information Update: 04 Nov 2020
At a glance
- Drugs Mirabegron (Primary) ; Tadalafil (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms CONTACT Study
- 05 Feb 2019 Status changed from active, no longer recruiting to completed.
- 18 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 16 Dec 2016 New trial record